- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- PB-119 100 μg+ Glucophage®, PB-119 150 μg+ Glucophage®, PB-119 200 μg+ Glucophage®, PB-119 placebo + Glucophage®
- Drug
- Lead sponsor
- PegBio Co., Ltd.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 985
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis
- Interventions
- Metformin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- placebo, taspoglutide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 29
- States / cities
- Bermuda Dunes, California • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
- Interventions
- Metformin hydrochloride
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Ann Arbor, Michigan
- Conditions
- Healthy
- Interventions
- Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
- Conditions
- NAFLD
- Interventions
- Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo
- Drug
- Lead sponsor
- NuSirt Biopharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Chino, California • San Diego, California • Wheat Ridge, Colorado + 10 more
- Conditions
- Prostate Cancer
- Interventions
- Metformin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dulaglutide, Placebo, Insulin Glargine, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 13
- States / cities
- Fresno, California • San Mateo, California • Tustin, California + 10 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PF-05175157, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- DeLand, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- Not listed
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
- Interventions
- Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Metformin
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Rimonabant, Placebo (for Rimonabant), Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Atrial Fibrillation
- Interventions
- Metformin
- Drug
- Lead sponsor
- The Guthrie Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Sayre, Pennsylvania
- Conditions
- Disability Physical, Wheelchair, Obesity; Overweight
- Interventions
- The Fast In-Bed Tracking System (FIT) Weight Scale, Group Lifestyle Balance Adapted for Individuals with Impaired Mobility (GLB-AIM) intervention
- Device · Behavioral
- Lead sponsor
- Jonathan Pearlman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia
- Interventions
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- AZD1656, Digoxin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 933 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Fresno, California • La Mesa, California • Lancaster, California + 26 more
- Conditions
- PreDiabetes
- Interventions
- Decision Aid intervention, Text Messaging intervention, Usual Care
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 960 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Erythroplakia, Oral Leukoplakia
- Interventions
- Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride, Placebo Administration
- Procedure · Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • San Diego, California • Tampa, Florida + 5 more
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Psyllium powder, Metformin Extended Release Oral Tablet
- Drug
- Lead sponsor
- West Side Institute for Science and Education
- Other
- Eligibility
- 20 Years to 70 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prediabetes / Type 2 Diabetes
- Interventions
- Metformin, GLP-1A, MED
- Drug · Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
- Interventions
- Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 10,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 6
- States / cities
- Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more